ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
MacroGenics Inc

MacroGenics Inc (MGNX)

4.37
0.26
(6.33%)
Closed June 22 4:00PM
4.34
-0.03
(-0.69%)
After Hours: 7:58PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
4.34
Bid
4.25
Ask
17.00
Volume
6,290,150
4.04 Day's Range 4.38
3.14 52 Week Range 21.88
Market Cap
Previous Close
4.11
Open
4.12
Last Trade Time
Financial Volume
$ 26,299,523
VWAP
4.1811
Average Volume (3m)
2,567,480
Shares Outstanding
62,633,460
Dividend Yield
-
PE Ratio
-30.15
Earnings Per Share (EPS)
-0.14
Revenue
58.75M
Net Profit
-9.06M

About MacroGenics Inc

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveragin... Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
MacroGenics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MGNX. The last closing price for MacroGenics was $4.11. Over the last year, MacroGenics shares have traded in a share price range of $ 3.14 to $ 21.88.

MacroGenics currently has 62,633,460 shares outstanding. The market capitalization of MacroGenics is $273.08 million. MacroGenics has a price to earnings ratio (PE ratio) of -30.15.

MGNX Latest News

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.34-7.264957264964.684.683.99513588784.23342795CS
4-0.29-6.263498920094.635.193.99515451614.46110575CS
12-10.36-70.476190476214.719.54083.1425674807.35998733CS
26-5.72-56.858846918510.0621.883.14189415510.53883277CS
52-1.35-23.72583479795.6921.883.1412373089.42957732CS
156-17.66-80.27272727272229.162.139089239.27693407CS
260-11.93-73.325138291316.2736.48042.1391073614.18958782CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

MGNX Discussion

View Posts
Money Management Money Management 4 weeks ago
Lucy runs
πŸ‘οΈ0
Dubster watching Dubster watching 1 month ago
Blessings sir!
πŸ‘οΈ0
Tom turtles Tom turtles 1 month ago
Well, I never got in. Thought it might of seen upper twos today. Watched it go up 30% though. Got in AMC for some reason. Glad someone made some money here.
πŸ‘οΈ0
Dubster watching Dubster watching 1 month ago
I thought I was going to take a loss on my bottom feeding expedition, but instead I am thankful that He blesses me!
πŸ‘οΈ0
Dubster watching Dubster watching 1 month ago
Bingo
πŸ‘οΈ0
Dubster watching Dubster watching 1 month ago
Finally sold some greened up.
I wait until the issues aren’t deaths
πŸ‘οΈ0
Tom turtles Tom turtles 1 month ago
$2.50 Monday ?
πŸ‘οΈ0
Dubster watching Dubster watching 1 month ago
These guys are getting hammered! 75%
πŸ‘οΈ0
Dubster watching Dubster watching 1 month ago
Down 75% this should be wild today!
πŸ‘οΈ0
Dubster watching Dubster watching 1 month ago
Took a starter, gotta gave a bounce here.
πŸ‘οΈ0
Dubster watching Dubster watching 1 month ago
Interesting drop today.
Hunting
πŸ‘οΈ0
stocksrising stocksrising 1 month ago
I’m with ya on entry..planning on a $3ish handle which equals cash on balance sheet( ~ $185mm ish)…. Will do starter in low $4’s(minor $$, then DCA if $3’s ( much more $) …back up truck if deaths not related to clinical’s after internal investigation)
πŸ‘οΈ0
Tom turtles Tom turtles 1 month ago
Well, 5 fatalities ready didn't help...geez...Looking for entry
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
MGNX new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
MGNX new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
MGNX new 52 week high
K
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
MGNX new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
MGNX
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
MGNX new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
MGNX new 52 week high
πŸ‘οΈ0
ipo_dude ipo_dude 6 months ago
Lets do this . Can it keep going
πŸ‘οΈ0
MiamiGent MiamiGent 6 months ago
MGNX $10.71 +1.48 (+16.03%)
Nice steady climb, as shorts writhe and wail
πŸ‘οΈ0
MiamiGent MiamiGent 6 months ago
MGNX I'm going with this
$10.50 +1.27 (+13.76%)
It's a bit of a bail, as I have other work to catch up on
Squeeze of 13% short, on a Citi upgrade to $13

Could turn into a several days hold, for incremental gains. Maybe 5% more today??

https://stockcharts.com/h-sc/ui?s=MGNX

Citigroup Upgrades Macrogenics to Buy, Raises Price Target to $13
BENZINGA 4:20 AM ET Dec-20-2023

Citigroup analyst Yigal Nochomovitz upgrades Macrogenics (MGNX.NaE) from Neutral to Buy and raises the price target from $7 to $13.


Company Profile
SectorHealth CareOpens in a new window
IndustryBiotechnologyOpens in a new window
Company LocationRockville, MD
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 x CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, i
πŸ‘οΈ0
ipo_dude ipo_dude 6 months ago
👀
πŸ‘οΈ0
ipo_dude ipo_dude 6 months ago
Shes ready to pop above $10
πŸ‘οΈ0
XenaLives XenaLives 1 year ago
Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Settlement Date/Short Interest/Percent Change/
Average Daily Share Volume/Days to Cover

01/13/2023 4,373,837 5.28 507,089 8.63
12/30/2022 4,154,346 7.91 575,736 7.22
12/15/2022 3,849,672 (5.66) 633,050 6.08
11/30/2022 4,080,607 (4.36) 1,384,683 2.95
11/15/2022 4,266,434 (15.78) 1,093,099 3.90
10/31/2022 5,065,570 2.50 1,487,531 3.41
10/14/2022 4,942,015 (0.29) 379,450 13.02
09/30/2022 4,956,490 1.85 563,681 8.79
09/15/2022 4,866,500 (0.81) 635,807 7.65
08/31/2022 4,905,995 (13.08) 631,036 7.77
08/15/2022 5,644,366 (0.09) 971,172 5.81
07/29/2022 5,649,639 (17.42) 1,065,799 5.30
07/15/2022 6,841,233 (10.73) 1,407,012 4.86
06/30/2022 7,663,135 (0.99) 2,692,200 2.85
06/15/2022 7,739,527 27.13 1,239,553 6.24
05/31/2022 6,088,004 8.28 827,523 7.36
05/13/2022 5,622,390 10.78 1,337,461 4.20
04/29/2022 5,075,315 3.20 453,486 11.19
04/14/2022 4,917,910 (4.48) 509,771 9.65
03/31/2022 5,148,635 3.46 522,723 9.85
03/15/2022 4,976,392 36.20 868,105 5.73
02/28/2022 3,653,830 4.57 898,618 4.07
02/15/2022 3,494,052 19.83 571,075 6.12
01/31/2022 2,915,828 7.17 457,915 6.37
πŸ‘οΈ0
XenaLives XenaLives 2 years ago
So what exactly did MGNX do to this diabetes drug?


MacroGenics to get $60M milestone from Provention as FDA approves diabetes drug Tzield


More homework:
https://patents.justia.com/assignee/macrogenics-inc
πŸ‘οΈ0
XenaLives XenaLives 2 years ago
Looking at MGNX because the chart is intriguing..

VBP is consolidating nicely...

πŸ‘οΈ0
XenaLives XenaLives 2 years ago
Now I need to figure out what DART and TRIDENT are...


Nov 17, 2022
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics. Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement.

β€œWe are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. β€œWe applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes.”

Under the agreement, Provention is obligated to pay MacroGenics contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to MacroGenics totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product.

Based on MacroGenics’ cash, cash equivalents and marketable securities balance as of September 30, 2022, plus projected and anticipated payments from partners, including timely receipt of the milestone payment from Provention, MacroGenics currently anticipates having a cash runway into late 2024.


http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-and-zai-lab-enter-broad-strategic-collaboration
πŸ‘οΈ0
XenaLives XenaLives 2 years ago
Nov 17, 2022
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics. Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement.

β€œWe are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. β€œWe applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes.”

Under the agreement, Provention is obligated to pay MacroGenics contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to MacroGenics totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product.

Based on MacroGenics’ cash, cash equivalents and marketable securities balance as of September 30, 2022, plus projected and anticipated payments from partners, including timely receipt of the milestone payment from Provention, MacroGenics currently anticipates having a cash runway into late 2024.

https://www.globenewswire.com/news-release/2022/11/17/2558767/0/en/MacroGenics-Earns-60-Million-Milestone-with-U-S-FDA-Approval-of-Teplizumab.html
πŸ‘οΈ0
makinezmoney makinezmoney 2 years ago
$MGNX: What did I tell ya........ hit $4.15 !!!!!!!!!


MUAHHHHhhhhhhhhhh ha ha ha ha ha haaaaaaaaaAAAAAAAAAAAAAA



LOVE IT when a plan comes together like that


Looking for more winners............ stand by


GO $MGNX
πŸ‘οΈ0
makinezmoney makinezmoney 2 years ago
$MGNX: Perfeccccccttttttttt Cup & Handle here at 3.50


Added 10k shares here


Get to $4 !!!!!!!!


GOO $MGNX
πŸ‘οΈ0
ipo_dude ipo_dude 4 years ago
Where do we go from here?
πŸ‘οΈ0
Now516 Now516 4 years ago
FDA approval: https://www.macrogenics.com/news/macrogenics-announces-fda-approval-of-margenza-for-patients-with-pretreated-metastatic-her2-positive-breast-cancer/
πŸ‘οΈ0
Glider549 Glider549 4 years ago
https://biopharmcatalyst.us13.list-manage.com/track/click?u=ce642b003b32103d28995373d&id=a988dba9aa&e=d1924831d6
πŸ‘οΈ0
rsconcept rsconcept 4 years ago
SCAM ALERT, be careful the SEC must be looking at it as we speak.
This is a $13-$16 stock at best.
πŸ‘οΈ0
rsconcept rsconcept 4 years ago
https://newsnation1.com/macrogenics-inc-mgnx-scam-news/
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $MGNX Video Chart 05-11-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Hercules1 Hercules1 4 years ago
$MGNX:

Nice to see shorts getting killed here.

Go ahead short some more you cowards.
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $MGNX Video Chart 05-07-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
davidsson10 davidsson10 4 years ago
+$$$ MGNX

Successful lifestyle enhancement trading.....
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $MGNX Video Chart 05-06-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
rsconcept rsconcept 4 years ago
great, lets short it again!
πŸ‘οΈ0
crudeoil24 crudeoil24 4 years ago
Investors are forward looking, especially into company pipeline.
πŸ‘οΈ0
PAC PAC 4 years ago
What i say? Retest after shakeout 19s
πŸ‘οΈ0
crudeoil24 crudeoil24 4 years ago
We all ran with this from earlier today. Shorts will have their cluster rama rally now. GLTY.
πŸ‘οΈ0
godofthestock godofthestock 4 years ago
TIMBER!!!!!!!


IMO
πŸ‘οΈ0
godofthestock godofthestock 4 years ago
This is going to be great IMO
πŸ‘οΈ0
crudeoil24 crudeoil24 4 years ago
No macaroni >
πŸ‘οΈ0
godofthestock godofthestock 4 years ago
Bio-Tech company?
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock